To Be Discontinued Tablet Antiviral
Atazanavir Sulfate; Cobicist · 312 days since initial FDA posting
Brand: EVOTAZ
FDA lists Atazanavir Sulfate; Cobicist as To Be Discontinued (Bristol Myers Squibb Co.).
No availability text on this FDA row.
Atazanavir Sulfate; Cobicistat Tablet: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Atazanavir Sulfate; Cobicistat Tablet
- Manufacturer
- Bristol Myers Squibb Co.
- Dosage Form
- Tablet
- Presentation
- Evotaz, Tablet, 300 mg; 150 mg (NDC 0003-3641-11)
- Package NDC
- 0003-3641-11
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Nov 3, 2025
- Last Updated
- Nov 3, 2025
- Therapeutic Category
- Antiviral
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
The global Cease Manufacture date for EVOTAZ® currently is estimated to begin April 2026.
FDA reason on file: The global Cease Manufacture date for EVOTAZ® currently is estimated to begin April 2026. General shortage guidance lives on the tracker hub.